![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1453940
Æ®¸®ºÎƼ¸°(Tributyrin) ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, ¼øµµ ¼öÁغ°, ¿ëµµº°, Áö¿ªº° ¼¼°è ºÐ¼®Tributyrin Market Forecasts to 2030 - Global Analysis By Type (Powder, Liquid and Other Types), Purity Level (Purity 45% and Below, Purity 45% - 99% and Purity 99% and Above), Application (Swine, Poultry and Other Applications) and by Geography |
Stratistics MRC¿¡ µû¸£¸é ¼¼°è Æ®¸®ºÎƼ¸° ½ÃÀåÀº 2023³â 1¾ï 3,748¸¸ ´Þ·¯·Î 2030³â¿¡´Â 2¾ï 9,455¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 11.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Æ®¸®ºÎƼ¸°Àº Æ®¸®±Û¸®¼¼¸®µå, Á¤È®È÷ ¸»ÇÏ¸é ´Ü¼â Áö¹æ»êÀÎ ºÎƼ¸£»êÀ¸·Î ¸¸µç Æ®¸®¿¡½ºÅ׸£ÀÔ´Ï´Ù. ±Û¸®¼¼·Ñ °ñ°Ý¿¡ ¿¡½ºÅ׸£È µÈ ¼¼ °³ÀÇ ºÎƼ¸£»ê ºÐÀÚ·Î ±¸¼ºµË´Ï´Ù. Æ®¸®ºÎƼ¸°Àº ÀϺΠÁö¹æ°ú ±â¸§¿¡ ÀÚ¿¬ÀûÀ¸·Î Á¸ÀçÇϸç, ±× Ư¼öÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ ½Äǰ »ê¾÷°ú Á¦¾à »ê¾÷¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇÁ·Îµå·¯±× ¿ªÇÒÀ» ÇÏ´Â ºÎƼ¸£»êÀº Ç׿°Áõ ¹× Ç×¾Ï ÀÛ¿ë°ú °°Àº ¿©·¯ °¡Áö °Ç°»óÀÇ ÀÌÁ¡°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù.
¹Ì±¹½ÉÀåÇùȸ¿¡ µû¸£¸é ±ÔÄ¢ÀûÀÎ ¿îµ¿°ú ±ÕÇü ÀâÈù ½Ä´ÜÀ» Æ÷ÇÔÇÑ °Ç°ÇÑ »ýȰ½À°üÀ» À¯ÁöÇÏ´Â °ÍÀÌ ½ÉÇ÷°ü °Ç°¿¡ ¸Å¿ì Áß¿äÇÏ´Ù°í ÇÕ´Ï´Ù.
¼Òȱ⠰ǰ¿¡ ´ëÇÑ Áö½ÄÀÇ Áõ°¡
´Ü¼âÁö¹æ»ê, ƯÈ÷ ºÎƼ¸£»êÀÌ Àå °Ç°¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ Æ®¸®ºÎƼ¸° ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ½Ä½À°üÀÌ °Ç°¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Æ®¸®ºÎƼ¸° ÇÔÀ¯ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ÒºñÀÚµéÀÌ ¼Òȱ⠰ǰÀ» ÁõÁø½ÃŰ´Â ±â´É¼º ½ÄǰÀ» ã°í Àֱ⠶§¹®¿¡ ½Äǰ »ê¾÷°ú °Ç° º¸Á¶ ½Äǰ »ê¾÷ÀÌ ÀÌ·¯ÇÑ Ãß¼¼¸¦ °¡Àå Àß º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.
°í°´ÀÇ Áö½Ä ºÎÁ·
Æ®¸®ºÎƼ¸°ÀÇ ÀáÀçÀû °Ç° È¿°ú¿¡ ´ëÇÑ °í°´ÀÇ Áö½Ä ºÎÁ·Àº ½ÃÀåÀÇ Å« Á¦¾àÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸¹Àº »ç¶÷µéÀÌ Æ®¸®ºÎƼ¸°¿¡ Àͼ÷ÇÏÁö ¾ÊÀº °ÍÀº ÀÌ ÈÇÕ¹°ÀÌ ´Ù¾çÇÑ ¼ÒºñÀÚ Á¦Ç°¿¡ ³Î¸® äÅõǴ µ¥ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Àå¾Ö¹°À» ±Øº¹ÇÏ°í Æ®¸®ºÎƼ¸°ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀÌÇØ¸¦ ÁõÁø½Ã۱â À§Çؼ´Â ±³À° ¹× È«º¸ Ä·ÆäÀÎÀÌ ÇʼöÀûÀÔ´Ï´Ù.
±â´É¼º ½Äǰ¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡
±â´É¼º ½Äǰ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Æ®¸®ºÎƼ¸° ½ÃÀåÀº Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ±âº»ÀûÀÎ ½Ä»ýȰÀ» ³Ñ¾î °Ç°»óÀÇ ÀÌÁ¡À» Á¦°øÇÏ´Â ±â´É¼º ½Äǰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü½Å °Ç°¿¡ µµ¿òÀÌ µÇ´Â ½ÄǰÀ» ã´Â ¼ÒºñÀÚÀÇ Ãß¼¼¿¡ µû¶ó ºÎƼ¸°Àº ´Ù¾çÇÑ ±â´É¼º ½Äǰ¿¡ ÷°¡µÇ¾î Àå °Ç°¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
Àå±âÀûÀÎ ¿µÇâ¿¡ ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÏ´Ù
Æ®¸®ºÎƼ¸°ÀÇ Àå±âÀûÀÎ ¿µÇâ¿¡ ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÏ¿© ½ÃÀå È®´ë°¡ À§Çù¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¿¹ºñ ¿¬±¸¿¡ µû¸£¸é ÀáÀçÀûÀÎ °Ç°»óÀÇ ÀÌÁ¡ÀÌ ÀÖÁö¸¸ öÀúÇϰí Àå±âÀûÀÎ ¿¬±¸°¡ ºÎÁ·ÇÏ¿© Æ®¸® ºÎƼ ¸°ÀÇ Àå±âÀûÀÎ ¾ÈÀü¼º°ú È¿´É¿¡ ´ëÇÑ ÀDZ¸½ÉÀ» ºÒ·¯ ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ¾ò±â À§Çؼ´Â ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇϱâ À§ÇØ Ã¶ÀúÇÑ ¿¬±¸¿Í ÀÓ»ó½ÃÇèÀ» ¼öÇàÇØ¾ß ÇÕ´Ï´Ù.
Æ®¸®ºÎƼ¸° ½ÃÀåÀº COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÀÔ ±â¾÷µéÀº ¼¼°è °ø±Þ¸ÁÀÇ È¥¶õ, Á¦Á¶ ¿î¿µÀÇ Á¦ÇÑ, °æÁ¦ ºÒÈ®½Ç¼º µîÀ¸·Î ÀÎÇØ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ °Ç°°ú À£ºù¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ƯÁ¤ °Ç°±â´É½Äǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇßÁö¸¸, ¼ÒºñÀÚ ÇൿÀÇ º¯È¿Í °æ±â ħü·Î ÀÎÇØ Àüü ½ÃÀåÀÇ ¼ºÀåÀÌ ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾×ü ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó
Æ®¸®ºÎƼ¸° ½ÃÀå¿¡¼ ¾×ü ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾×»ó Æ®¸®ºÎƼ¸°Àº ´Ù¾çÇÑ ¿ëµµ¿¡ Àû¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¤È®ÇÑ ¿ë·®À» ½±°Ô ÃøÁ¤Çϰí Åõ¿©ÇÒ ¼ö ÀÖ´Â Á¦¾à ¾÷°è¿¡¼ ƯÈ÷ ¼±È£ÇÕ´Ï´Ù. µ¿¹° ¿µ¾çÇп¡¼µµ ¾×ü ºÎƼ¸°Àº »ç·á¿¡ ½±°Ô ¹èÇÕÇÒ ¼ö ÀÖ¾î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À¯µ¿¼ºÀ¸·Î ÀÎÇØ È¿°úÀûÀΠȥÇÕÀÌ ¿ëÀÌÇϱ⠶§¹®¿¡ ±ÕÀÏÇÑ Á¦Ç° ¹èÇÕÀÌ ÇÊ¿äÇÑ »ê¾÷¿¡¼ ±ÇÀåµÇ´Â ¼±ÅÃÀÔ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¼øµµ 99% ÀÌ»óÀÇ ºÎ¹®ÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÎƼ¸° ½ÃÀå¿¡¼ ¼øµµ 99% ÀÌ»óÀÇ ºÎ¹®ÀÌ °¡Àå ³ôÀº CAGRÀ» º¸À̰í ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷ÀÇ Ä¡·á¿ë Á¦Á¦¿¡´Â Á¤¹ÐÇÏ°í ¼ø¼öÇÑ ÈÇÕ¹°ÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ °í¼øµµ ºÎƼ¸°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í¼øµµ ºÎ¹®Àº Á¦¾à »ê¾÷ÀÌ Æ®¸®ºÎƼ¸°À» ÇÁ·Îµå·¯±×(prodrug)·Î »ç¿ëÇÏ´Â ÀǾàǰ, ƯÈ÷ ºÎƼ¸£»ê(butyric acid)ÀÇ Àü´Þ¿¡ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®¿¡ °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ư¼ö ½Äǰ ¹× °í±Þ ÈÀåǰ°ú °°ÀÌ Á¦ÇüÀÇ Á¤È®¼ºÀ» ¿ì¼±½ÃÇÏ´Â »ç¾÷¿¡¼´Â ¼øµµ 99% ÀÌ»óÀÇ Æ®¸®½Ç¸°À» ¼±È£ÇÕ´Ï´Ù.
À¯·´ Áö¿ªÀº Àü ¼¼°è Æ®¸®ºÎƼ¸° »ê¾÷¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´ ½ÃÀåÀÇ °Á¡Àº »ï÷ÆÇ¸·ÀÇ ÀǾàÀû Ȱ¿ë¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ´Â Á¦¾à »ê¾÷ÀÌ È°¼ºÈµÇ¾î Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ±â´É¼º ½Äǰ°ú °Ç°±â´É½ÄǰÀ» ÅëÇØ ¼Òȱ⠰ǰÀ» ÁõÁøÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ¾î Æ®¸³Æ¿¸°À» ÇÔÀ¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯·´¿¬ÇÕ(EU)ÀÇ µ¿¹° ¿µ¾ç »ê¾÷ÀÌ È®¸³µÇ¾î Àֱ⠶§¹®¿¡ Æ®¸®ºÎƼ¸°Àº °¡Ãà »ç·á ÷°¡Á¦·Î ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. À¯·´ ¼ÒºñÀÚÀÇ °Ç°°ú º¹Áö¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ÇÔ²² Æ®¸³Æ¿¸° ½ÃÀå È®´ë°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
¼¼°è Æ®¸®ÄÚ¸Þ¸° ½ÃÀå¿¡¼ ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Æø¹ßÀûÀÎ ¼ºÀåÀÇ ¿øµ¿·ÂÀº Á¦¾à ¹× ÀÇ·á ºÐ¾ßÀÇ ¼ºÀå°ú Æ®¸®½ÃÆ¿¸°ÀÇ °Ç°»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÏ¹Ý ´ëÁßÀÇ Áö½ÄÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¹æÀû °Ç°°ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, ½Ä½À°ü º¯È, °¡Ã³ºÐ ¼Òµæ Áõ°¡´Â ¸ðµÎ Æ®¸®½ÃÆ¿¸°À» ÇÔÀ¯ÇÑ ±â´É¼º ½Äǰ ¹× °Ç°±â´É½Äǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹° ¿µ¾ç »ê¾÷ÀÇ ¼ºÀå°ú °¡Ãà °Ç°¿¡ ´ëÇÑ °ü½ÉÀº µ¿¹° »ç·á¿¡ ºÎƼ¸°À» ÷°¡ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Tributyrin Market is accounted for $137.48 million in 2023 and is expected to reach $294.55 million by 2030 growing at a CAGR of 11.5% during the forecast period. Tributyrin is a triglyceride, or more precisely, a triester made from the short-chain fatty acid butyric acid. It consists of three butyric acid molecules esterified to a glycerol backbone. Tributyrin, which is naturally present in some fats and oils, is widely used in the food and pharmaceutical industries due to its special qualities. Acting as a prodrug, butyric acid has been linked to several health advantages, such as its anti-inflammatory and anti-cancer characteristics.
According to the American Heart Association, maintaining a healthy lifestyle, including regular physical activity and a balanced diet, is crucial for cardiovascular well-being.
Growing knowledge about digestive health
Due to growing consumer awareness of the critical role that short-chain fatty acids, especially butyric acid, play in supporting gut health, the tributyrin market is expanding significantly. Product demand for tributyrin-containing products is increasing as people become more aware of how their diet affects their overall health. Moreover, the food and nutritional supplement industries are showing this trend most clearly as consumers look for functional foods that promote digestive health.
Insufficient knowledge of customers
Customer's lack of knowledge about tributyrin's potential health benefits is a major market constraint. The compound's widespread adoption in various consumer products may be hampered by the lack of familiarity with it among a large number of people. Additionally, to overcome this obstacle and promote consumer comprehension of tributyrin's advantages, education and awareness campaigns are essential.
Growing awareness of functional foods
The market for tributyrin has a lot of potential because of the growing consumer interest in functional foods. More people are becoming aware of functional foods, which provide health advantages over a basic diet. Furthermore, gaining from the trend of consumers looking for foods that support their overall well-being, butyrin can be added to a range of functional food products and may have a positive effect on gut health.
Insufficient studies on prolonged impacts
The expansion of the market may be threatened by the paucity of studies on tributyrin's long-term effects. Although preliminary research indicates possible health advantages, a dearth of thorough, extended investigations could give rise to doubts regarding the long-term safety and effectiveness of tributyrin. Moreover, gaining the trust of consumers requires conducting thorough research and clinical trials to close this gap.
The tributyrin market has experienced a variety of effects from the COVID-19 pandemic. Market participants have faced difficulties as a result of disruptions in the global supply chain, limitations on manufacturing operations, and economic uncertainties. The demand for specific nutritional supplements has been fueled by the pandemic's increased consumer awareness of health and wellness, but overall market growth has been restrained by changes in consumer behavior and economic downturns.
The Liquid segment is expected to be the largest during the forecast period
In the market for tricytyrin, the liquid segment has the largest share. Tributyrin in liquid form is preferred due to its adaptability to a wide range of applications, especially in the pharmaceutical industry, where accurate dosages are simple to measure and administer. Animal nutrition also makes extensive use of liquid butyrin, which is easy to incorporate into feed formulations. Because of its fluidity, which facilitates effective mixing, it is a recommended option for industries where product formulations must be uniform.
The Purity 99% and Above segment is expected to have the highest CAGR during the forecast period
In the trichome market, the segment of purity of 99% and above has the highest CAGR. Because precise and pure compounds are necessary for therapeutic formulations in the pharmaceutical industry, there is a growing demand for high-purity butyrin. The high-purity segment has experienced robust growth due to the pharmaceutical industry's emphasis on research and development of drugs that use tributyrin as a prodrug, especially for the delivery of butyric acid. Moreover, businesses that prioritize formulation accuracy, like specialty food items and high-end cosmetics, favor tricyrin that has a purity level of 99% or higher.
The region of Europe is projected to possess the largest market share in the worldwide tributyrin industry. The strength of the European market stems from a thriving pharmaceutical industry that conducts extensive research on the medicinal uses of tricuspid valves. The demand for products containing tricyrin has increased due to the region's growing emphasis on promoting digestive health through functional foods and nutraceuticals. Furthermore, tributyrin's acceptance as a feed additive for livestock can be attributed to the European Union's well-established animal nutrition industry. European consumers growing consciousness of health and well-being, combined with strict regulatory frameworks, has made the market for tricytyrin growth conducive to expansion.
In the global trichomerin market, the Asia-Pacific region exhibits the highest CAGR. The growing pharmaceutical and healthcare sectors, along with growing public knowledge of the health advantages of tricytyrin, are driving the region's explosive growth. Growing emphasis on preventive healthcare, shifting dietary habits, and rising disposable income all contribute to the demand for functional foods and dietary supplements that contain tributyrin. Moreover, the growth of the animal nutrition industry in Asia-Pacific and the focus on livestock health are the main factors behind the addition of butyrin to animal feed formulations.
Key players in the market
Some of the key players in Tributyrin market include Perstorp Holding AB, Hangzhou FandaChem Co., Ltd., Shanghai Smart Chemicals Co., Ltd., Jefo Nutrition Inc., Kemcolour International, Vetagro S.p.A, Penta Manufacturer, TCI Development Co., Ltd, Prinova Group LLC and Merck KGaA.
In February 2024, Sweden-based specialty chemicals company Perstorp has built and commissioned a new ISCC Plus-certified plant in western India to meet the growing market demand for Penta chemicals. Located in Sayakha, Bharuch, in the state of Gujarat, the facility was officially inaugurated on Feb. 20. This is the largest investment in Asia so far, in Perstorp's history. It will further strengthen Perstorp's position as a sustainable and reliable partner in the region of Asia, commented Gorm Jensen, Perstorp's Executive Vice President Commercial & Innovation.
In December 2023, Transcargo International, TCI, a veteran terminal operator in Egypt, announces the signing of an agreement with Sinai White Portland Cement, SWCC, for the development of Egypt's first bulk cement silos in Arish Port, marking a significant milestone in the cement industry in Egypt and its export capabilities.
In December 2023, Merck has signed an agreement in Germany for the commercialisation of products that include or contain Abbisko Therapeutics' pimicotinib (ABSK021) for all indications. Merck will receive an exclusive licence to market the products in licensed territories comprising the Chinese mainland, Hong Kong, Macau and Taiwan. The exclusive rights for the development of pimicotinib in the licensed territories will be retained by Abbisko.